Khan, Nasreen http://orcid.org/0000-0001-6184-0503
Cabo, Raquel
Burdine, Rebecca D.
Tan, Wen-Hann
Keary, Christopher J.
Ochoa-Lubinoff, Cesar
Bird, Lynne M.
,
Funding for this research was provided by:
Ovid Therapeutics Inc
Article History
Accepted: 12 December 2022
First Online: 11 April 2023
Declarations
:
: Dr. Khan is a paid consultant for Ovid Therapeutics. Ms. Cabo is an employee of Ovid Therapeutics. Dr. Burdine consults on clinical trials supported by Ovid Therapeutics. Dr. Tan has participated in clinical trials supported by Ovid Therapeutics and Dimension Therapeutics and has also received research support from Ovid Therapeutics. Dr. Keary has consulted for Ovid Therapeutics and is participating in clinical trials supported by Ovid Therapeutics. Dr. Ochoa-Lubinoff has consulted for Ovid Therapeutics and participated in clinical trials supported by Ovid Therapeutics. Dr. Bird is participating in clinical trials supported by Ovid Therapeutics.
: Protocol approval and ethics oversight was provided by the regional IRBs/ECs at each site. Written informed consent was obtained from the legally authorized representative of each participating individual, prior to any study procedures.
: Not applicable.